Updates
** Shares of drug developer Lyra Therapeutics LYRA.O soar 648.5% to a more than year high of $36.90
** Stock set for its best day on record, if gains hold
** As of last close, co had market cap of $6.53 mln, on track to add about $42.4 mln to market cap, if gains hold
** Lyra's experimental drug LYR-210 met the main and secondary goals of a late-stage trial; reduced symptoms of Chronic Rhinosinusitis $(CRS)$, including nasal congestion, discharge, and facial pain, in patients without nasal growths (polyps)
** Chronic rhinosinusitis is a chronic inflammation of the nasal passages and sinuses
** LYR-210 is a bioabsorbable nasal implant that delivers six months of continuous dosage for patients with the condition
** Co plans to pursue FDA approval of the drug for patients without nasal polyps and continue developing the drug for people with nasal polyps
** The company had $31.7 million in cash and cash equivalents as of March 31
** As of last close, LYRA stock down 52.2% YTD
(Reporting by Padmanabhan Ananthan and Kamal Choudhury)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.